Nanologica AB (publ) (STO:NICA)

Market Cap	154.19M +20.8%
Revenue (ttm)	31.83M +57.2%
Net Income	24.07M
EPS	0.26
Shares Out	328.77M
PE Ratio	1.80
Forward PE	9.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4490
Previous Close	0.4520
Day's Range	0.4410 - 0.4690
52-Week Range	0.3300 - 2.2500
Beta	-0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Nanologica AB

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 72
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NICA

Financial Performance

In 2025, Nanologica AB's revenue was 21.13 million, an increase of 45.32% compared to the previous year's 14.54 million. Losses were -51.29 million, -21.85% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 13, 2026

Data Sources Report a data error